Skip to main content
Caplight Logo









Sperogenix Therapeutics

Sperogenix Therapeutics

Private
BeijingHealthcare & Life Scienceshttps://sperogenix.com/

Last Round

Series B

Oct 23, 2023

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Sperogenix Therapeutics is a pharmaceutical company that develops and commercializes rare disease therapeutics in China.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

rare disease therapeuticsbiopharmaceuticalin-licensingDuchenne muscular dystrophyDMDvamoroloneorphan drugsclinical developmentregulatory navigationbiotech licensingneuromuscular disordersmetabolic disordersdrug commercializationX-linked adrenoleukodystrophyX-ALD

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Sperogenix Therapeutics Comparables

Compare Sperogenix Therapeutics with similar companies based on industry and business-model similarity.

Sperogenix Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
CS Pharmaceuticals
78%
Hongkong Winhealth Pharma Group
78%
CANbridge Pharma
72%

Sperogenix Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BOct 23, 2023

Key People

Founding team and executive leadership

Alan Yan

Co-founder & CEO

Founding Team

Sperogenix Therapeutics Investors

Notable investors and investment history

Sperogenix Therapeutics investors
InvestorRounds
Morningside VenturesSeries A
Jingxu Venture CapitalSeries A
Lilly Asia VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 26, 2026

    Monthly visitors grew 695% MoM, from 255 to 2K.

  • Jul 1, 2025

    Monthly visitors increased 138% MoM.

Sperogenix Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Sperogenix Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Sperogenix Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBeijing
Employee Range15
Year Founded2019
Last FundingOct 23, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?